Those ‘not significant’ exceptions include some statistical tests on outcome measures of weight loss and overall QoL in one feasibility study in cancer survivors [127], some biomarkers including the monocyte chemoattractant protein-1 (MCP-1), NADPH oxidase p47, and the inducible nitric oxide synthase protein (iNOS) [122], stress hormone cortisol and IL-6 [128], and low-density lipoprotein (LDL) [122]. This evidence concerns the gene NOS2 and cancer.